Hookworm infection is common, treatable, and rarely discussed with the seriousness it deserves given how many people it affects worldwide. Ivermectin is often the first drug people think of when they hear "parasite," but the honest answer for hookworm specifically is more nuanced than many online sources suggest. This article lays out what hookworm is, what the actual clinical evidence says about ivermectin against it, how dosing works when a physician does choose to use it, and why a different, older drug remains the standard of care. The goal is not to talk anyone out of a treatment their doctor recommends, but to make sure a patient walks into that conversation informed.
What hookworm is and why it matters
Hookworm disease is caused mainly by two species of intestinal roundworm, Necator americanus and Ancylostoma duodenale. Larvae typically enter the body through skin contact with contaminated soil, migrate through the bloodstream and lungs, and mature in the small intestine, where adult worms attach to the intestinal wall and feed on blood. Infection is concentrated in warm, humid regions with inadequate sanitation, and the World Health Organization estimates that several hundred million people carry some form of soil-transmitted helminth infection at any given time, hookworm among the most significant of them.
Light infections often cause few symptoms. Heavier, chronic infections cause the problem that matters most clinically: iron-deficiency anemia from ongoing blood loss, along with protein loss, fatigue, and in children, impaired growth and cognitive development. Pregnant women are especially vulnerable, since hookworm-related anemia compounds the normal physiologic demands of pregnancy. This is a disease where treating the parasite is genuinely an act of stewardship over a body, and often a family's future, not just a lab result to correct.
Where ivermectin actually fits in modern practice
Ivermectin is a genuinely important medicine. It is derived from avermectin, a compound isolated from the soil bacterium Streptomyces avermitilis, discovered by the Japanese microbiologist Satoshi Ōmura and developed into ivermectin by William Campbell at Merck. Their work was recognized with the Nobel Prize in Physiology or Medicine in 2015, largely because ivermectin transformed the control of river blindness (onchocerciasis) and lymphatic filariasis across Africa and Latin America. It is a striking example of a medically useful compound emerging from ordinary soil, the kind of quiet providence worth noticing in how the natural world has been arranged.
Ivermectin works by binding to glutamate-gated chloride channels found in the nerve and muscle cells of nematodes and other invertebrates. This causes paralysis and death of the parasite. These particular channels are not present in mammalian cells in the same form, and in mammals ivermectin is largely excluded from the central nervous system by a transport protein at the blood-brain barrier, which is part of why the drug has such a favorable safety record at approved doses.
In the United States, ivermectin (brand name Stromectol, among generics) is FDA-approved for two human indications: strongyloidiasis and onchocerciasis. It is not FDA-approved for hookworm. It is also used off-label, with reasonable supporting evidence, for scabies and sometimes as part of combination mass drug administration programs targeting lymphatic filariasis. When it is used against hookworm, that use is off-label, and it happens far less often than people searching online might assume.
The actual evidence for ivermectin against hookworm
This is the part worth being direct about. Ivermectin is excellent against Strongyloides stercoralis, a different soil-transmitted roundworm that is frequently confused with hookworm in casual conversation because both are acquired through skin contact with soil. Against genuine hookworm species, the evidence is considerably weaker.
A widely cited systematic review published in JAMA in 2008 (Keiser and Utzinger, pooling results from dozens of clinical trials of anthelmintic drugs against soil-transmitted helminths) found that single-dose albendazole achieved cure rates for hookworm in the range of roughly 70 to 80 percent, a genuinely strong result. Ivermectin, by contrast, performed substantially worse and less consistently across the trials that examined it, with cure rates well below those seen with albendazole. Subsequent trials and reviews over the following decade have generally reinforced that pattern: ivermectin can reduce worm burden and egg output somewhat, but it does not reliably clear hookworm infection the way it clears strongyloidiasis or the way albendazole clears hookworm.
The likely biological reason is that hookworm's attachment site and feeding behavior in the gut differ from the parasites ivermectin was developed and refined against, and the drug's pharmacokinetics in the human gut do not sustain the exposure needed to kill adult hookworms as reliably as it kills the larvae and adults of other species. None of this makes ivermectin a bad drug; it simply means it is the wrong tool for this particular job, and good medicine means matching the tool to the target rather than reaching for whichever medicine is most familiar.
What is actually recommended: albendazole and mebendazole
For hookworm specifically, the World Health Organization and the CDC recommend the benzimidazole drugs, principally albendazole (usually a single 400 mg dose in adults) or mebendazole, as first-line treatment. These drugs work by a different mechanism, disrupting the parasite's microtubule structure and starving it of glucose, and albendazole in particular has consistently shown the highest cure and egg-reduction rates against hookworm in head-to-head trials. These are the drugs used in the large-scale deworming programs run in schools and communities across endemic regions, precisely because the evidence supporting them for this specific parasite is so much stronger.
This matters for anyone asking what the "best treatment for hookworm" actually is: the honest, evidence-based answer is albendazole or mebendazole, not ivermectin, and a physician diagnosing hookworm by stool examination will almost always reach for one of those two first.
If ivermectin is used, dosing and what to expect
There are clinical situations where a physician might still choose ivermectin, for instance when hookworm and strongyloidiasis are both suspected or confirmed, or in mixed-infection settings where combination therapy is being considered. When ivermectin is prescribed for its approved indications, dosing is weight-based, given as a single oral dose taken on an empty stomach with water, generally in the range of 150 to 200 micrograms per kilogram of body weight. In practical terms, using the standard tablet strengths available (commonly 3 mg, with other strengths such as 6, 9, or 12 mg used to match weight bands), an adult weighing roughly 65 to 84 kilograms would typically correspond to a 12 mg dose, while a person in the 15 to 24 kilogram range might receive 3 mg. These weight bands are why the "12 mg" and "3 mg" tablet strengths show up so often in searches; they are dosing units tied to body weight, not different products with different jobs.
Ivermectin is absorbed fairly quickly, reaching peak blood levels within about four hours, with an elimination half-life of around 18 hours. Any effect on a susceptible parasite begins within days, but clinical follow-up for intestinal parasites is judged by repeat stool examination, generally performed two to three weeks after treatment, rather than by symptoms alone, since light infections can be asymptomatic even while worms remain present. If ivermectin is used off-label for hookworm and follow-up testing shows the infection persists, the appropriate next step is not simply repeating the same drug but switching to albendazole or mebendazole, which is precisely why most physicians reach for those drugs first rather than second.
Side effects from a single approved dose of ivermectin are usually mild: dizziness, nausea, mild itching, or drowsiness. It is generally avoided in children weighing under 15 kilograms, used with added caution in pregnancy given limited safety data, and requires specific caution in parts of Central Africa where a related parasite, Loa loa, is common, because mass ivermectin treatment in heavily Loa-infected individuals has been associated with rare but serious neurological reactions. This is a good example of why self-treatment based on an internet search is not a substitute for a stool test and a conversation with a physician who knows the patient's travel history, weight, and other medications.
The responsible way to approach treatment
None of this evidence argues against medical freedom or a patient's right to understand their options; if anything, it argues for it more strongly. A patient who understands that ivermectin and albendazole are not interchangeable for hookworm is better equipped to ask their doctor the right question, request the right stool test, and confirm cure with follow-up testing rather than assuming symptoms alone tell the whole story. Treating a family member for a parasite picked up from soil, water, or travel is exactly the kind of everyday responsibility that good stewardship of health looks like: taking it seriously, getting an accurate diagnosis, and using the drug the evidence actually supports.
Key takeaway: For confirmed hookworm infection, albendazole or mebendazole is the evidence-based first-line treatment, while ivermectin—though a valuable drug for strongyloidiasis and onchocerciasis—has shown weaker and less consistent results against hookworm and should only be used for it under a physician's guidance.